Our Website Uses Cookies 


We and the third parties that provide content, functionality, or business services on our website may use cookies to collect information about your browsing activities in order to provide you with more relevant content and promotional materials, on and off the website, and help us understand your interests and improve the website.


For more information, please contact us or consult our Privacy Notice.

Your binder contains too many pages, the maximum is 40.

We are unable to add this page to your binder, please try again later.

This page has been added to your binder.

Andrew Ment
Andrew W. Ment
Partner
New York +1 212 841 1012 ament@cov.com Download V-card

Andrew Ment’s practice focuses on mergers and acquisitions and private equity transactions.  Mr. Ment’s M&A experience includes public and private acquisitions and divestitures, leveraged buy-outs, “going private” transactions and joint ventures.  Mr. Ment also practices in the area of corporate finance, where his experience includes syndicated lending, royalty sales & financings, registered offerings, and private placements.

  • Forest Laboratories, Inc. in its $1.2 billion acquisition of Clinical Data, Inc. and its $357 million acquisition of the U.S. patents and other US and Canadian intellectual property related to Bystolic®.
  • eScreen, Inc. in its sale to Alere, Inc. for $270 million upfront and up to $70 million in contingent payments.
  • Bristol-Myers Squibb Company in its acquisition of Amira Pharmaceuticals for $325 million upfront and up to $150 million in contingent payments.
  • Procter & Gamble in the $3.1 billion sale of its pharmaceuticals business to Warner-Chilcott.
  • Snow Phipps Group in its acquisition of Service Champ, Inc. and in its acquisition of Acentia (formerly ITSolutions) and multiple follow-on acquisitions by the Acentia portfolio company.
  • Northwestern University in the sale of a portion of its worldwide royalty interest in Lyrica for $700 million.
  • Oregon Steel Mills, Inc. in its $2.3 billion merger into Evraz Group S.A.
  • Abbott Laboratories in its $3.7 billion acquisition of Kos Pharmaceuticals, Inc.
  • Kerr-McGee Corporation in its $18 billion merger into Anadarko Petroleum Corporation.

Previous Experience

  • Economic Consulting Services Inc., Staff Economist (1993-1995)
  • Legal 500 US, Mergers, Acquisitions & Buyouts: M&A (2013-2014)